AtaiBeckley Files Proxy for $3.91B Eli Lilly Acquisition, Board Unanimously Recommends Vote FOR
ATAI has more than doubled off its 52-week low of $3.265.
Summary
AtaiBeckley filed a preliminary proxy statement for its acquisition by Eli Lilly for $6.75 per share in cash plus contingent value rights (CVRs) worth up to an additional $2.50 per share, which the board unanimously recommends.
Key Events · M&A and Partnerships · ATAI
-
Acquisition Terms Finalized for Shareholder Vote
Eli Lilly will acquire AtaiBeckley for $6.75 per share in cash plus one Contingent Value Right (CVR) per share, potentially adding up to $2.50 per share based on clinical and regulatory milestones. The total transaction value is approximately $3.91 billion, representing a 40% premium to the 30-day volume-weighted average trading price.
-
Board Unanimously Recommends Merger Approval
AtaiBeckley's Board of Directors unanimously determined the merger agreement is advisable, fair, and in the best interests of the company and its shareholders, recommending a 'FOR' vote on the adoption of the merger agreement.
-
Key Shareholder Support Agreements in Place
Directors, executive officers, and the largest shareholder, Apeiron Investment Group Ltd., collectively holding over 15% of common stock, have entered into voting and support agreements to vote in favor of the merger.
-
CVR Milestones Detailed
The CVRs are contingent on three milestones: $1.00 for VLS-01 Phase 3 trial initiation (within 4 years), $0.50 for BPL-003 U.S. regulatory approval and DEA rescheduling (within 5 years), and $1.00 for VLS-01 U.S. regulatory approval and DEA rescheduling (within 7 years). Lilly is obligated to use commercially reasonable efforts to achieve these milestones.
Analysis · ATAI · Life Sciences
This preliminary proxy statement details the terms and rationale for AtaiBeckley's acquisition by Eli Lilly, a significant event for the company and its shareholders. The deal offers immediate cash consideration of $6.75 per share and potential additional value of up to $2.50 per share through CVRs tied to key clinical and regulatory milestones for its lead product candidates, BPL-003 and VLS-01. The unanimous board recommendation and voting agreements from major shareholders underscore strong internal support for the transaction, which provides a substantial premium and liquidity to shareholders while leveraging Lilly's resources for pipeline development.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 42.3% of the 496 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATAI was trading at $7.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $3.27 to $7.22. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.